Navidea Biopharmaceuticals (NAVB -4.3%) slips on disappointment that the FDA is giving a six...

|About: Navidea Biopharmaceuticals (NAVB)|By:, SA News Editor

Navidea Biopharmaceuticals (NAVB -4.3%) slips on disappointment that the FDA is giving a six month window to approve Lymphoseek, its Lymphoma diagnostic tool, rather than the two-month review time-frame some investors were betting on. The agency had rejected NAVB's first application in September, citing problems caused by its third-party manufacturer, and it now has to re-inspect the manufacturing site before deciding on the drug.